(BLTE) Belite Bio - Overview
Stock: Tinlarebant, LBS-009, Retinal, Liver, Metabolic
| Risk 5d forecast | |
|---|---|
| Volatility | 74.6% |
| Relative Tail Risk | -25.3% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 2.39 |
| Alpha | 215.38 |
| Character TTM | |
|---|---|
| Beta | 0.349 |
| Beta Downside | 0.564 |
| Drawdowns 3y | |
|---|---|
| Max DD | 66.63% |
| CAGR/Max DD | 1.25 |
Description: BLTE Belite Bio January 13, 2026
Belite Bio, Inc. (NASDAQ:BLTE) is a clinical-stage biopharma focused on oral therapeutics for retinal degenerative diseases, primarily Stargardt disease type 1 and geographic atrophy (GA), which together affect an estimated 1.5 million U.S. adults and represent a multi-billion-dollar market opportunity driven by an aging population.
Its lead candidate, Tinlarebant (LBS-008), is in a Phase 3 trial as an early-intervention oral drug intended to preserve retinal tissue health. The trial targets a primary endpoint of slowing lesion growth measured by fundus autofluorescence, with an interim analysis expected in Q4 2024.
Belite’s secondary pipeline includes LBS-009, an anti-retinol-binding protein 4 (RBP4) oral agent currently in preclinical development for non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), type 2 diabetes, and gout-indications collectively accounting for > $30 billion in U.S. healthcare spend.
From a financial standpoint, as of the latest 10-Q (ended June 30 2024), the company reported cash and cash equivalents of roughly $45 million, giving it an estimated runway into 2025 assuming current burn rates (~$12 million per quarter). The market cap sits near $70 million, implying a price-to-cash ratio of about 1.5×, which is low relative to the biotech median of ≈ 3× for companies with Phase 3 assets.
For a deeper dive into Belite Bio’s valuation metrics, you might explore the analysis on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.02 > 0.02 and ΔFCF/TA 24.18 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.02 > 3% & CFO -4.60m > Net Income -62.4m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 34.37 > 1.5 & < 3 |
| Outstanding Shares: last quarter (33.2m) vs 12m ago 8.26% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%) |
| Interest Coverage Ratio: -2165 > 6 (EBITDA TTM -61.0m / Interest Expense TTM 20.0k) |
Altman Z'' -15.00
| A: 0.95 (Total Current Assets 277.2m - Total Current Liabilities 8.07m) / Total Assets 282.4m |
| B: -0.57 (Retained Earnings -159.9m / Total Assets 282.4m) |
| C: -0.22 (EBIT TTM -43.3m / Avg Total Assets 199.1m) |
| D: -19.24 (Book Value of Equity -159.9m / Total Liabilities 8.31m) |
| Altman-Z'' Score: -17.26 = D |
What is the price of BLTE shares?
Over the past week, the price has changed by +11.16%, over one month by +17.28%, over three months by +68.14% and over the past year by +218.19%.
Is BLTE a buy, sell or hold?
- StrongBuy: 3
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the BLTE price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 192.1 | 2.3% |
| Analysts Target Price | 192.1 | 2.3% |
| ValueRay Target Price | 289.9 | 54.3% |
BLTE Fundamental Data Overview February 07, 2026
P/B = 24.9603
Revenue TTM = 0.0 USD
EBIT TTM = -43.3m USD
EBITDA TTM = -61.0m USD
Long Term Debt = 510.0k USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 276.0k USD (from shortTermDebt, last fiscal year)
Debt = 537.0k USD (from shortLongTermDebtTotal, last fiscal year)
Net Debt = -31.1m USD (from netDebt column, last fiscal year)
Enterprise Value = 6.53b USD (6.69b + Debt 537.0k - CCE 157.0m)
Interest Coverage Ratio = -2165 (Ebit TTM -43.3m / Interest Expense TTM 20.0k)
EV/FCF = -1000.0x (Enterprise Value 6.53b / FCF TTM -4.61m)
FCF Yield = -0.07% (FCF TTM -4.61m / Enterprise Value 6.53b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 449.0k) / Revenue TTM)
Tobins Q-Ratio = 23.14 (Enterprise Value 6.53b / Total Assets 282.4m)
Interest Expense / Debt = 3.72% (Interest Expense 20.0k / Debt 537.0k)
Taxrate = 21.0% (US default 21%)
NOPAT = -34.2m (EBIT -43.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 34.37 (Total Current Assets 277.2m / Total Current Liabilities 8.07m)
Debt / Equity = 0.00 (Debt 537.0k / totalStockholderEquity, last quarter 274.1m)
Debt / EBITDA = 0.51 (negative EBITDA) (Net Debt -31.1m / EBITDA -61.0m)
Debt / FCF = 6.76 (negative FCF - burning cash) (Net Debt -31.1m / FCF TTM -4.61m)
Total Stockholder Equity = 182.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -31.33% (Net Income -62.4m / Total Assets 282.4m)
RoE = -34.29% (Net Income TTM -62.4m / Total Stockholder Equity 182.0m)
RoCE = -23.73% (EBIT -43.3m / Capital Employed (Equity 182.0m + L.T.Debt 510.0k))
RoIC = -16.29% (negative operating profit) (NOPAT -34.2m / Invested Capital 210.0m)
WACC = 7.20% (E(6.69b)/V(6.69b) * Re(7.20%) + D(537.0k)/V(6.69b) * Rd(3.72%) * (1-Tc(0.21)))
Discount Rate = 7.20% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 8.32%
Fair Price DCF = unknown (Cash Flow -4.61m)
EPS Correlation: -10.72 | EPS CAGR: 26.73% | SUE: 4.0 | # QB: 1
Revenue Correlation: N/A | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.64 | Chg30d=-0.002 | Revisions Net=-2 | Analysts=4
EPS next Year (2026-12-31): EPS=-1.24 | Chg30d=-0.645 | Revisions Net=+0 | Growth EPS=+42.6% | Growth Revenue=+0.0%